Biotest AG Logo

Biotest AG

ISIN

DE0005227235

Ticker

BIO3

Sector

Health Care

Sub-Industry

Biotechnology

Country

Germany

Year Founded

1946

About Biotest AG

Company Description

Biotest is a global company that supplies plasma protein products and biotherapeutic drugs. Our products are primarily used in the therapeutic areas of clinical immunology, haematology and intensive care medicine. For patients with serious and often chronic diseases they provide targeted treatment, which generally enable them to lead almost normal lives.
Within our areas of specialisation, we start from pre-clinical and clinical development to manufacturing and global marketing. Research, development and production are carried out at our main headquarters in Germany. Our own sales organisations (subsidiaries) and cooperating partners represent our global distribution network.

Headcount

1,663

Served Area

Worldwide

Headquarters

Landsteinerstraße 5
63303, Dreieich
Germany

Filings & Publications

  • Consolidated Report 2022 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2022 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2022 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2022 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2022 - Q4 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2022 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2021 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2021 - Q4 German πŸ‡©πŸ‡ͺ
  • Remuneration Report 2021 - Q4 German πŸ‡©πŸ‡ͺ
  • Remuneration Report 2021 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q2 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q2 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2020 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2020 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q1 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q1 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2019 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2019 - Q4 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2018 - Q3 English πŸ‡¬πŸ‡§
  • Consolidated Report 2018 - Q3 German πŸ‡©πŸ‡ͺ
  • Consolidated Report 2018 - Q4 English πŸ‡¬πŸ‡§
  • Consolidated Report 2018 - Q4 German πŸ‡©πŸ‡ͺ

Insider Trades

Date Trading entity / Person Association Trade type Volume
29.11.2021 BernΓΆster, Dr. Katrin Other Sell EUR 15,640.00
29.11.2021 Realsoul Holding S.A. Close relation Buy EUR 1,713.60
18.11.2021 Fleck, Stephan Other Sell EUR 120,870.00
18.11.2021 SchΓΌttrumpf, Dr. JΓΆrg Other Sell EUR 99,895.50
18.11.2021 Reinecke, Dr. Martin Other Sell EUR 37,715.00
18.11.2021 Moritz, Michael Other Sell EUR 35,460.00

Capital Markets Information

ISIN

DE0005227235

LEI

529900JVX7RPXBLYUD89

Sub-Industry

Biotechnology

Listed Stock Exchange

Frankfurt Stock Exchange

Contact Investor Relations Department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.